Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F18%3A00078033" target="_blank" >RIV/00209805:_____/18:00078033 - isvavai.cz</a>
Alternative codes found
RIV/00216224:14310/18:00101544
Result on the web
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29196895" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/29196895</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1007/7651_2017_111" target="_blank" >10.1007/7651_2017_111</a>
Alternative languages
Result language
angličtina
Original language name
Targeted Proteomics Driven Verification of Biomarker Candidates Associated with Breast Cancer Aggressiveness
Original language description
Breast cancer is the most common and molecularly well-characterized malignant cancer in women; however, its progression to metastatic cancer remains lethal for 78% of patients within 5 years of diagnosis. Identifying novel markers in high risk patients using quantitative methods is essential to overcome genetic, inter-tumor, and intra-tumor variability, and to translate novel findings into cancer diagnosis and treatment. Using untargeted proteomics, we recently identified 13 proteins associated with some key factors of breast cancer aggressiveness: estrogen receptors, tumor grade, and lymph node status. Here we verified these findings in a set of 96 tumors using targeted proteomics based on selected reaction monitoring with mTRAQ labeling (mTRAQ-SRM). This study highlights a panel of gene products that could contribute to breast cancer aggressiveness and metastasis, and can help develop more precise breast cancer treatments.
Czech name
—
Czech description
—
Classification
Type
C - Chapter in a specialist book
CEP classification
—
OECD FORD branch
30204 - Oncology
Result continuities
Project
<a href="/en/project/GA17-05957S" target="_blank" >GA17-05957S: Evaluation of novel potential targets and inhibitors to block metastasis development in luminal A breast cancer</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2018
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Book/collection name
Tissue Proteomics: Methods in molecular biology
ISBN
978-1-4939-7852-6
Number of pages of the result
8
Pages from-to
1-8
Number of pages of the book
320
Publisher name
Springer
Place of publication
New York
UT code for WoS chapter
—